Shattuck Labs Announces Participation in Upcoming September Conferences
Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company, announced its participation in two investor conferences in September 2022. The first event is Citi's 17th Annual BioPharma Conference on September 8, where CEO Taylor Schreiber will present at 2:40 p.m. ET. The second event is H.C. Wainwright's 24th Annual Global Investment Conference on September 12 at 7:00 a.m. ET. Both presentations will be available via live webcast on the company's website, with replays accessible for up to 90 days.
- Participation in two prominent investor conferences may enhance visibility for STTK.
- Presentations led by the CEO could strengthen investor relations and confidence.
- None.
AUSTIN, TX & DURHAM, NC, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in two investor conferences in September 2022.
Presentation Details
Conference: Citi’s 17th Annual BioPharma Conference
Format: Targeted Oncology panel discussion with covering analyst Yigal Nochomovitz
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: September 8, 2022
Time: 2:40 p.m. ET
Conference: H.C. Wainwright 24th Annual Global Investment Conference
Format: Corporate Presentation
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: September 12, 2022
Time: 7:00 a.m. ET
A live webcast of the presentations will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
What are the dates of the upcoming conferences for Shattuck Labs (STTK)?
Who will represent Shattuck Labs at the investor conferences?
Will the presentations from Shattuck Labs be available online?
What time will Shattuck Labs present at the Citi BioPharma Conference?
What time will Shattuck Labs present at the H.C. Wainwright Conference?
